Friday 6 November 2026 Export XERS’s income statement to Excel — free account

Xeris Biopharma Holdings, Inc.

XERS Healthcare Drug Manufacturers Specialty & Generic

Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.

Revenue: +44.2%
EPS: +1,479.0%
Free cash flow: +93.2%
Total debt: −13.6%

Quarter to September 2026, against a year earlier

15.16 2.08 +15.90%

Follow XERS

Alert me

Market cap: $2.4B
P/E: 0.0×
Fwd P/E: −143×
Dividend yield: —
F-score: 8/9
Altman Z: 0.98
Beneish M: −2.58
Dividend safety: n/a

Overview

Xeris Biopharma Holdings, Inc. (XERS) P/S ratio

Alert me on P/S ratio

As of 6 November 2026, Xeris Biopharma Holdings, Inc. (XERS) trades at a P/S ratio of 7.4×. Over the past ten years it has ranged from 0.0× (June 2018) to 282× (November 2018); the current reading is higher than 64% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.1× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/XERS/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Xeris Biopharma Holdings, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/XERS/metrics/ps-ratio">Xeris Biopharma Holdings, Inc. (XERS) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	4.3×	76.11%
FY2024	2.5×	28.51%
FY2023	1.9×	38.38%
FY2022	1.4×	(70.49%)
FY2021	4.7×	(54.52%)
FY2020	10.3×	(84.82%)
FY2019	67.6×	(19.99%)
FY2018	84.5×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	P/S ratio	Change
Sep 2026	4.7×	15.10%
Jun 2026	4.1×	29.91%
Mar 2026	3.1×	(27.20%)
Dec 2025	4.3×	(13.79%)
33 more quarters	Free account

Against its own ten years

Low 0.0× High 282×

Ten-year median 4.3×

Current reading's percentile 64

Company	P/S ratio
HCM HUTCHMED (China) Limited Sponsored ADR compare	n/m
PRGO Perrigo Company plc compare	0.5×
PBH Prestige Consumer Healthcare Inc. compare	1.7×
BCRX BioCryst Pharmaceuticals, Inc. compare	2.0×
TRLV Trulieve Cannabis Corp. compare	2.1×
ALVO Alvotech compare	4.8×
XERS Xeris Biopharma Holdings, Inc.	7.4×
AMLX Amylyx Pharmaceuticals, Inc. compare	37.3×
RGC Regencell Bioscience Holdings Limited compare	—
Drug Manufacturers Specialty & Generic industry median	2.1×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Xeris Biopharma Holdings, Inc. (XERS) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on XERS

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on XERS

Stockrow Weekly